With all the principals having close professional ties to Morehouse School of Medicine, Jyant Technologies, Inc. is a development-stage biotechnology company developing novel therapies for Crohn's Disease. Jyant had earlier developed a protein which binds to but does not activiate specific ligands in the intestine which, when triggered, can lead to colitis -- inflamation of the colon and is a common symptom of Crohn's disease.
